These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7739499)

  • 21. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
    Koning N; Swaab DF; Hoek RM; Huitinga I
    J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early glial responses in murine models of multiple sclerosis.
    Ayers MM; Hazelwood LJ; Catmull DV; Wang D; McKormack Q; Bernard CC; Orian JM
    Neurochem Int; 2004; 45(2-3):409-19. PubMed ID: 15145555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis.
    Hafler DA; Slavik JM; Anderson DE; O'Connor KC; De Jager P; Baecher-Allan C
    Immunol Rev; 2005 Apr; 204():208-31. PubMed ID: 15790361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathology of multiple sclerosis and its evolution.
    Lassmann H
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1635-40. PubMed ID: 10603616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligodendrocytes and the early multiple sclerosis lesion.
    Prineas JW; Parratt JD
    Ann Neurol; 2012 Jul; 72(1):18-31. PubMed ID: 22829266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid precursor protein (APP) expression in multiple sclerosis lesions.
    Gehrmann J; Banati RB; Cuzner ML; Kreutzberg GW; Newcombe J
    Glia; 1995 Oct; 15(2):141-51. PubMed ID: 8567065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pathology and definition of multiple sclerosis].
    Dutta R; Trapp BD
    Rev Prat; 2006 Jun; 56(12):1293-8. PubMed ID: 16948216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Magnetic Resonance Imaging study of the role of the blood-brain barrier in the pathogenesis of experimental allergic encephalomyelitis: application to multiple sclerosis].
    Chambron J; Namer IJ; Steibel J; Gounot D; Armspach JP
    Bull Acad Natl Med; 1994 Dec; 178(9):1647-63; discussion 1663-5. PubMed ID: 7788436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathogenesis of multiple sclerosis: status of research].
    Hartung HP
    Wien Med Wochenschr; 1996; 146(19-20):520-7. PubMed ID: 9082652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.
    Onuki M; Ayers MM; Bernard CC; Orian JM
    Microsc Res Tech; 2001 Mar; 52(6):731-9. PubMed ID: 11276125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Butyrylcholinesterase activity in multiple sclerosis neuropathology.
    Darvesh S; Leblanc AM; Macdonald IR; Reid GA; Bhan V; Macaulay RJ; Fisk JD
    Chem Biol Interact; 2010 Sep; 187(1-3):425-31. PubMed ID: 20122907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood-brain barrier changes in multiple sclerosis.
    Trojano M; Manzari C; Livrea P
    Ital J Neurol Sci; 1992 Dec; 13(9 Suppl 14):55-64. PubMed ID: 1345741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostaglandins in pathogenesis and treatment of multiple sclerosis.
    Mirshafiey A; Jadidi-Niaragh F
    Immunopharmacol Immunotoxicol; 2010 Dec; 32(4):543-54. PubMed ID: 20233088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pathological anatomy in multiple sclerosis].
    Duma D; Câmpeanu E; Serban M
    Neurol Psihiatr Neurochir; 1968; 13(6):503-14. PubMed ID: 5719425
    [No Abstract]   [Full Text] [Related]  

  • 35. Curcumin has bright prospects for the treatment of multiple sclerosis.
    Xie L; Li XK; Takahara S
    Int Immunopharmacol; 2011 Mar; 11(3):323-30. PubMed ID: 20828641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models.
    Junker A; Brück W
    Curr Opin Neurol; 2012 Jun; 25(3):349-57. PubMed ID: 22543404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral infection at the blood-brain barrier in multiple sclerosis:--an ultrastructural study of tissues from a UK Regional Brain Bank.
    Kirk J; Zhou AL
    Mult Scler; 1996 Feb; 1(4):242-52. PubMed ID: 9345442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired channelopathies as contributors to development and progression of multiple sclerosis.
    Schattling B; Eggert B; Friese MA
    Exp Neurol; 2014 Dec; 262 Pt A():28-36. PubMed ID: 24656770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological differences between white and grey matter multiple sclerosis lesions.
    Prins M; Schul E; Geurts J; van der Valk P; Drukarch B; van Dam AM
    Ann N Y Acad Sci; 2015 Sep; 1351():99-113. PubMed ID: 26200258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fungal toxins and multiple sclerosis: a compelling connection.
    Purzycki CB; Shain DH
    Brain Res Bull; 2010 Apr; 82(1-2):4-6. PubMed ID: 20214953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.